Introduction
Ovarian cancer is the fifth leading cause of cancer-related deaths in women. According to the GLOBOCAN 2012 database, the incidences of ovarian cancer are 9.1 per 1,00,100 in developed countries and 5.0 per 1,00,000 in developing countries. 1 Thereinto, approximately 70% is high-grade serous carcinomas. 2 Up to now, despite the effective treatments including radical resection, systemic chemotherapy, and targeted drugs for patients, the average 5-year survival is still only at 46%. 3 Ovarian cancer is a multifactorial disease caused by the interaction of genetic and epigenetic factors. 4, 5 DNA methylation, as the most common epigenetic alteration, could occur at CpG island in the promoter region, 5′ or 3′ untranslated regions, and even in gene body of tumor suppressor genes (TSGs). Hypermethylation in the proximal promoter region often contributes to the transcriptional downregulation but methylation in exons is associated with active transcription. 6, 7 Recently, mounting evidences demonstrated that DNA methylation was involved in ovarian cancer. [8] [9] [10] Therefore, identifying the role of TSG methylation in patients with ovarian cancer is of value.
P16
INK4a (also known as CDKN2A), a classical TSG, is located on chromosome 9p21 and plays an important role in cell cycle regulation by decelerating cells progression from G1 to S phase. 11, 12 It has become clear that the expression of P16 is reduced by DNA methylation. [13] [14] [15] Also, P16
INK4a
inactivation upregulates retinoblastoma (RB) protein by stimulating the cyclin-dependent kinases (CDKs) and RB pathway, which leads to dysfunction of cell proliferation and apoptosis, thereby further facilitating carcinogenesis. 16 Indeed, several types of cancer, including ovarian cancer, exhibit a methylation phenotype of P16
. [17] [18] [19] To date, even though abundant studies have been conducted to explore the role of P16 INK4a promoter methylation in ovarian cancer, the results are still inconclusive. Several studies reported that P16
INK4a promoter methylation was associated with an increasing trend in ovarian cancer, [20] [21] [22] [23] while, other studies suggested that P16
INK4a promoter methylation was not related to the occurrence of ovarian cancer. [24] [25] [26] [27] [28] [29] [30] Interestingly, even the conclusions in two published meta-analyses were inconsistent. Xiao et al reported that aberrant methylation of P16 INK4a was significantly associated with ovarian carcinogenesis, 31 while Jiang et al suggested no association between P16 INK4a methylation and epithelial ovarian cancer. 32 Considering these conflicting conclusions on the role of methylated P16
INK4a in ovarian cancer, we performed an adaptive synthesized analysis to quantitatively evaluate the occurrence frequency, clinicopathological features, and potential prognostic significance of P16 INK4a promoter methylation in ovarian cancer. Moreover, we searched The Cancer Genome Atlas (TCGA) database, collecting hundreds of ovarian cancer samples with whole genome DNA methylation datasets to validate our meta-analysis.
Materials and methods

Search strategy and selection criteria
PubMed, Embase, Web of Science, and China National Knowledge Infrastructure were searched up to April 12, 2017 , by the following keywords and search items: (P16 OR P16 INK4a OR CDKN2A) AND (methylation OR hypermethylation OR demethylation) AND (ovarian OR ovary) AND (cancer OR carcinoma OR neoplasm). The search was limited to human studies, without language restriction. Moreover, a manual search of the relevant references was implemented to identify the potentially additional articles.
The following criteria were used for screening eligible studies: 1) case-control studies evaluating the association between P16
INK4a promoter methylation and ovarian cancer risk, or case only studies evaluating the association of P16
INK4a
promoter methylation with clinicopathological features or prognosis in ovarian cancer; 2) articles providing sufficient information for calculating an odds ratio (OR) and corresponding 95% CI, or study offering hazard ratio (HR) and 95% CI directly; 3) sample types limited to tissues; and 4) studies with full-text articles. It is worth noting that when multiple reports were published from a same study population, only the most recent or complete information was included in this meta-analysis. Meanwhile, studies with Newcastle Ottawa Scale (NOS) scores greater than or equal to five were enrolled.
Data extraction and quality assessment
With a preformed unified form, data were extracted independently by two investigators, and disagreements were resolved by discussion till consensus was achieved. The following information was extracted from studies: the first author's name, publication year, country, geographical location, sample size, age of patients in the case group, the frequencies of methylation in the case and control groups, methods for detecting methylation, methylation site, disease stage, tumor grade, histological subtype, and effects on survival outcomes.
The quality of eligible case-control studies was assessed according to the NOS criteria. 33 The NOS criteria are based on three aspects: 1) subject selection: 0-4; 2) comparability of subject: 0-2; 3) clinical outcome: 0-3. >50% indicated substantial heterogeneity, and then the random-effects model was applied. Otherwise, the fixed-effects model was selected. We also explored sources of heterogeneity using meta-regression and subgroup analyses by publication year, geographical location, method, and case sample size. Additionally, sensitivity analysis was performed to investigate the influence of individual study. 
Statistical analysis
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INK4a methylation in ovarian cancer worth mentioning that, for some trials containing no events in both case and control arms, as no information supplied about the likely magnitude of the effect, we excluded such trials when synthesizing data. 34 
TCGA datasets extraction and analysis
We collected DNA methylation datasets of 582 ovarian cancer cases and 12 ovarian normal tissues from TCGA ("TCGAovary [OV]" project) program. 35 The methylation measurement was performed using Illumina HumanMethylation27 BeadChip. Beta value of each CpG site was extracted to assess the methylation level of CDKN2A gene. Beta value was calculated based on the intensities of the methylated (M) and unmethylated (U) bead types: beta value = M/(M+U). 36 The difference of DNA methylation level of CpG sites between ovarian tumor tissues and normal ovarian tissues in TCGA database was analyzed by Student's t-test on the means.
P16
INK4a gene expression value (fragments per kilobase of transcript per million mapped reads) in ovarian tumor tissues (TCGA, "TCGA-OV" project) was also extracted. Pearson's product-moment correlation between P16 INK4a gene expression levels and methylation of its CpG islands was evaluated. Data analysis was performed using R software (R i386 3.4.0). P-values were adjusted via Bonferroni correction.
Results
Identification of relevant studies
The procedure of study selection is outlined in Figure 1 . We identified 233 articles in the initial literature search. A total of 153 references remained after removing duplicates. After reading titles and abstracts, 84 records were identified for further full-text assessment, which further excluded 60 more We defined n<50 as small size and ≥50 as large size. b Turkey is a transcontinental eurasian country and is usually assigned to Asia internationally. c egypt is a transcontinental country spanning the northeast corner of Africa and southwest corner of Asia, usually assigned to Africa internationally. 
3037
P16
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Quantitative data synthesis Figure 3) .
With large heterogeneity, meta-regression and subgroup analyses were conducted by the publication year, geographical location, method, and case sample size in the comparison of cancer tissues vs normal tissues. Meta-regression found that case sample size was significantly correlated with the interstudy heterogeneity (P=0.041) while other covariates were not (Table 3) . Furthermore, as shown in Figure 5A ). After considering potential confounders by adjusting for age at diagnosis Figure  5B ). Survival analysis also showed that P16 INK4a promoter methylation reduced OS in univariate and multivariate Cox regression models (HR =1.28, 95% CI=0.97-1.68; HR =1.16, 95% CI=0.87-1.55, respectively; Figure 5C and D), but the differences were not statistically significant.
Sensitivity analysis and publication bias
As presented in Figure 6A -C, no single study significantly affected the pooled ORs in the sensitivity analysis, indicating our analysis was relatively stable and credible. Funnel plots and Begg's test were used to evaluate the publication bias. The funnel plots were largely symmetric suggesting there were no publication biases in the meta-analysis of P16 22 Bhagat et al 2014 20 Dhillon et al 2004 23 Li et al 2006 27 Liu et al 2005 28 Makarla et al 2005 29 Makarla et al 2005 29 Makarla et al 2005 29 Ozdemir et al 2012 24 Rathi et al 2002 30 Shen et al 2008 25 Tam Cul'bová et al 2011 38 Gu et al 2009 39 Ho et al 2012 37 McCluskey et al 1999 47 Cul'bová et al 2011 38 Bhagat et al 2014 20 Bhagat et al 2014 20 McCluskey et al 1999 47 Moselhy et al 2015 17 Wiley et al 2006 
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INK4a methylation in ovarian cancer promoter methylation and ovarian cancer risk, which was confirmed by the Begg's test ( Figure 6D-F Table 4 , the beta values of 582 ovarian tumor tissues and 12 normal ovarian tissues were extracted for analysis. Obviously, the methylation levels of seven out of nine CpG sites were significantly increased in the ovarian tumor tissues compared with the normal tissues (cg03079681, cg07752420, cg09099744, cg10895543, cg11653709, cg12840719, and cg26673943). Among these regions, methylation level of probe cg26673943 region (located at the promoter region of P16
INK4a
) was negatively associated with P16 INK4a expression 20 Bhagat et al 2014 20 Hashiguchi et al 2001 44 Katsaros et al 2004 43 Shen et al 2008 25 Yang et al 2006 41 Bhagat et al 2014 20 Hashiguchi et al 2001 44 Katsaros et al 2004 43 Shen et al 2008 25 Yang 28 Bhagat et al 2014 20 Cul'bová et al 2011 38 Hashiguchi et al 2001 44 Katsaros et al 2004 43 Makarla et al 2005 29 McCluskey et al 1999 47 Milde-Langosch et al 1998 48 Shen et al 2008 25 Yang 
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INK4a methylation in ovarian cancer promoter region or non-promoter region has contrary effects on P16 INK4a gene expression.
Discussion
Ovarian cancer is one of the leading causes of cancer-related deaths in women. 50 Identification of early disease indicators for diagnosis and prognosis is of clinical value. P16 INK4a , which resembles classic TSGs such as P53, is an important negative regulator of cell growth and proliferation. 16 It has been synthetically evaluated for aberrant P16
INK4a methylation in numerous cancers, [51] [52] [53] [54] including ovarian cancer. 31, 32 Considering the conflicting conclusions in two meta-analyses and the lack of comprehensive assessment on the role of methylated P16 INK4a in ovarian cancer, we performed an adaptive synthesized analysis to investigate the relationships between P16 INK4a promoter methylation and ovarian cancer risk, as well as clinicopathological features and prognostic value in ovarian cancer. Meanwhile, we searched TCGA data to validate our meta-analysis.
Our meta-analysis demonstrated that P16 INK4a promoter methylation in cancer tissues was significantly higher than that in normal tissues (P<0.05), but not much increased than that in benign tissues. Compared with normal tissues, the frequency of P16 INK4a promoter methylation was 2.28-fold higher in both benign tissues and LMP tissues (P>0.05), but the differences were not statistically significant. The reason for this phenomenon may be that the transformation of normal cells to cancer cells is a long-term, gradual, and 
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Ruan et al multiphase process. 55 Although not establishing a strong correlation between P16
INK4a promoter methylation and cancer progression, the above results do suggest a possibility that epigenetic alteration of P16 INK4a promoter methylation might play a certain role in ovarian carcinogenesis and might be useful in distinguishing malignant tumor from healthy ovarian tissues. Considering the evident heterogeneity, we conducted subgroup analyses based on probable covariates in the comparison of cancer tissues vs normal tissues. For geographical location, P16
INK4a promoter methylation is a risk factor in Asia and Africa, but not in America. The divergence may be underscored in a large part to a combination of differences in allele frequencies and complex epistasis or gene-environment interactions. 56 A review also outlined that some factors such as distinct physical appearance, behavior, and response to environ- Bhagat et al 2014 20 Ozdemir et al 2012 24 Abou-Zeid et al 2011 22 Shen et al 2008 25 Tam et al 2007 26 Li et al 2006 27 Makarla et al 2005 29 Liu et al 2005 28 Dhillon et al 2004 23 Rathi et al 2002 30 Lower CI 
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INK4a methylation in ovarian cancer mental agents and drugs between human populations could have contributed to the epigenetic variations. 57 Similar findings appeared in the subgroup analyses of different methods and publication year. Kurdyukov and Bullock 58 suggested that it was essential to choose an appropriate method in a suitable region to answer a particular biological question in studies of DNA methylation. Additionally, the 95% CI was large in the group of small sample size while relatively small in the group of large sample size, implying the conclusion may not be reliable unless studies should be conducted using a sufficient number of samples. Previous studies also demonstrated that the methylation status in blood samples or fluids might be different from that in tissues. 59, 60 Thus, our results should be interpreted with caution because sample types were limited to tissues in studies included in this meta-analysis.
Previous studies indicated that P16 INK4a promoter methylation was associated with poorly differentiated tumors and was different in histological subtype in ovarian cancer. 22, 43 However, we could not establish any significant correlations between P16
INK4a promoter methylation and clinicopathological features, including age, clinical stage, tumor differentiation or histological subtype in this study. Therefore, it might not be essential to predict the invasion and metastasis of ovarian cancer.
Katsaros et al 43 and Wiley et al 42 reported association of P16 INK4a promoter methylation with PFS and OS in ovarian cancer, while Bhagat et al 20 found no significant value in predicting prognosis. In the present study, we discovered that P16
INK4a promoter methylation represented a risk factor for PFS. For OS, patients with P16 INK4a promoter methylation also had a slightly elevated risk, though the differences are not statistically significant. This trend was also observed in other types of cancer. 51, 54 However, its statistical confirmation requires large studies. The data from TCGA also indicated that methylation level of probe cg26673943 region (located at the promoter region of P16 INK4a ) in the ovarian tumor tissues was higher than normal ovarian tissues. Increased methylation of CpG island at the promoter region was negatively associated with P16
INK4a gene expression, while methylation of CpG islands at non-promoter regions was positively associated with P16
INK4a expression. Compared with previous meta-analyses, 31 ,32 our metaanalysis had several improvements. First, the development of ovarian cancer is a multistep procedure involving normal tissues, benign disease, LMP or borderline tumor, and malignant tumor. 20 We compared malignant ovarian cancer with LMP tumors, benign disease, and normal samples to give more rigorously to the analysis. Second, with 1,217 malignant ovarian cancer patients, 116 LMP, 271 benign patients, and 351 normal samples, the sample size in our study is much larger than that of all previous meta-analyses. Finally, we included the clinicopathological features and prognostic significance of P16 INK4a promoter methylation in ovarian cancer for more comprehensive understanding of the underlying pathogenesis of ovarian cancer. These strengths make our study a useful effort in seeking better understanding of the P16 INK4a promoter methylation in ovarian cancer.
Limitations
Several potential limitations in our current study should be noted. First, the heterogeneity was still large after subgroup analyses in the assessment of the association between P16
INK4a
promoter methylation and ovarian cancer risk, which may 
